查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1974061

放射性藥物生產市場分析及預測（至2035年）：類型、產品類型、服務、技術、應用、劑型、最終用戶、製程、設備、解決方案

Radiopharmaceutical Manufacturing Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Form, End User, Process, Equipment, Solutions
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

放射性藥物生產市場預計將從2024年的55億美元成長到2034年的130億美元，複合年成長率約為9%。放射性藥物生產市場涵蓋用於醫學成像和治療的放射性化合物的生產。這些化合物在核子醫學中至關重要，對包括癌症和心血管疾病在內的多種疾病的診斷和治療起著關鍵作用。推動市場成長的因素包括分子成像技術的進步、慢性病發病率的上升以及對個人化醫療日益成長的需求。此外，對監管合規性和放射性藥物生產製程技術創新的高度重視也進一步推動了市場成長。

放射性藥物生產市場持續穩定成長，這主要得益於核醫的進步和癌症發生率的上升。治療性放射性藥物領域處於領先地位，這主要得益於標靶癌症治療的日益普及。在該領域中，BETA和α發射體是表現最佳的子領域，它們能夠提供精準的治療方案，且副作用極小。診斷性放射性藥物領域緊隨其後，其中PET和SPECT示蹤劑憑藉其卓越的成像能力發揮主導作用。心血管和神經系統疾病盛行率的不斷上升進一步推動了對這些診斷試劑的需求。放射性藥物生產領域的新興技術，例如自動化合成模組和迴旋加速器技術的進步，正在提高生產效率和擴充性。此外，製藥公司與研究機構之間的合作正在促進創新，並加速新型放射性藥物的研發。嚴格的法規結構和品質標準確保了這些產品的安全性和有效性，從而提升了市場信譽和醫療服務提供者的信任度。

市場區隔
種類 診斷放射性藥物、治療放射性藥物、研究放射性藥物
產品 Technetium-99m、碘-131、氟代脫氧葡萄糖（FDG）、鎵-68、釔-90、鎦-177、鐳-223
服務 契約製造、品質保證、法規支援、物流和供應鏈管理
科技 迴旋加速器、核子反應爐、發電機、線性加速器
應用領域 腫瘤科、心臟科、神經科、內分泌科
形式 液體、固體、氣體
最終用戶 醫院、診斷中心、學術研究機構、製藥公司
流程 合成、純化、貼標、包裝
裝置 PET掃描器、SPECT掃描器、伽馬攝影機
解決方案 影像解決方案、治療解決方案、放射性藥物解決方案

市場概況：

放射性藥物生產市場正經歷動態的市場佔有率分佈，這主要受策略定價和創新產品推出的驅動。主要企業正致力於拓展產品組合，並推出新型放射性藥物，以滿足日益成長的精準醫療需求。這項策略擴張得益於核醫的進步和慢性病盛行率的上升。該市場的特點是競爭激烈的定價策略，力求在價格可負擔性和最尖端科技之間取得平衡，從而確保更廣泛的患者群體能夠獲得所需藥物。放射性藥物生產市場的競爭異常激烈，主要企業透過技術創新和策略聯盟爭奪主導。監管的影響至關重要，嚴格的指導方針塑造市場行為，並確保藥物的安全性和有效性。北美和歐洲憑藉其健全的法規結構保持主導地位，而亞太地區正在崛起為一個盈利的成長區域。持續的研發正在推動診斷和治療領域的新應用，為市場帶來了光明的前景。

主要趨勢和促進因素：

放射性藥物製造市場在分子成像技術和標靶治療進步的推動下持續穩定成長。主要趨勢包括PET和SPECT成像技術的日益普及，這些技術能夠提高診斷準確性並提供個人化治療方案。癌症和心血管疾病的日益普及推動了對這些技術的需求，這些技術能夠實現早期檢測和有效監測。監管部門的核准以及製藥公司與研究機構之間的合作正在加速放射性藥物的創新。新型放射性同位素和放射性標記化合物的開發正在擴大治療範圍，為市場參與者創造盈利的機會。此外，人工智慧（AI）與診斷成像系統的整合正在提高診斷能力，進一步推動市場成長。對醫療基礎設施（尤其是在新興國家）的投資不斷增加，正在推動新製造設施的建設。政府旨在改善先進醫療技術可近性的措施也支持了這一趨勢。預計這些因素將共同推動市場持續成長，以滿足對精準高效診斷解決方案日益成長的需求。

限制與挑戰：

放射性藥物生產市場面臨許多重大限制與挑戰。監管的複雜性構成了一大障礙，放射性藥物的生產和分銷受到嚴格的監管。遵守這些法規需要投入大量的時間和資源，這可能會阻礙創新和市場准入。另一個挑戰是生產所需的原料（尤其是同位素）供應有限。這種短缺會擾亂供應鏈，影響生產計劃，並增加成本。此外，生產設施和設備的高成本也構成了沉重的財務負擔，尤其對於新參與企業。該市場也面臨著對高技能專業人才的需求。由於該行業的特殊性，招募和留住熟練的專業人才至關重要，但也極具挑戰性。最後，公眾對放射性物質的認知和安全擔憂可能會阻礙市場成長，因此需要製定強力的教育和傳播策略來建立信任。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 診斷用放射性藥物
    • 治療性放射性藥物
    • 研究用放射性藥物
  • 市場規模及預測：依產品分類
    • Technetium-99m
    • 碘-131
    • 氟代脫氧葡萄糖（FDG）
    • 鎵-68
    • 釔-90
    • 鎦-177
    • 鐳-223
  • 市場規模及預測：依服務分類
    • 契約製造
    • 品質保證
    • 監管支持
    • 物流與供應鏈管理
  • 市場規模及預測：依技術分類
    • 迴旋加速器
    • 核子反應爐
    • 發電機
    • 直線加速器
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 心臟病學
    • 神經病學
    • 內分泌學
  • 市場規模及預測：依類型
    • 液體
    • 固體的
    • 氣體
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診斷中心
    • 學術研究機構
    • 製藥公司
  • 市場規模及預測：依製程分類
    • 合成
    • 純化
    • 符號
    • 包裝
  • 市場規模及預測：依設備分類
    • PET掃描儀
    • SPECT掃描儀
    • 伽馬攝影機
  • 市場規模及預測：按解決方案分類
    • 影像解決方案
    • 治療方案
    • 放射性藥物解決方案

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Advanced Accelerator Applications
  • Blue Earth Diagnostics
  • ITM Isotopen Technologien Munchen
  • Cyclopharm
  • NorthStar Medical Radioisotopes
  • Jubilant Radiopharma
  • Sofie Biosciences
  • Shine Medical Technologies
  • Eckert & Ziegler
  • Isotopia Molecular Imaging
  • Curium Pharma
  • Trace-Ability
  • Telix Pharmaceuticals
  • Alpha Tau Medical
  • Radiomedix

第9章：關於我們

簡介目錄
Product Code: GIS34194

Radiopharmaceutical Manufacturing Market is anticipated to expand from $5.5 billion in 2024 to $13 billion by 2034, growing at a CAGR of approximately 9%. The Radiopharmaceutical Manufacturing Market encompasses the production of radioactive compounds used in medical imaging and therapy. These compounds, integral to nuclear medicine, are pivotal for diagnosing and treating various conditions, including cancer and cardiovascular diseases. The market is driven by advancements in molecular imaging, increasing prevalence of chronic diseases, and rising demand for personalized medicine. Emphasis on regulatory compliance and technological innovation in radiopharmaceutical production processes further propels market growth.

The Radiopharmaceutical Manufacturing Market is experiencing robust expansion, propelled by advancements in nuclear medicine and increased incidence of cancer. The therapeutic radiopharmaceuticals segment is at the forefront, driven by the rising adoption of targeted cancer therapies. Within this segment, beta emitters and alpha emitters are top-performing sub-segments, offering precise treatment options with minimal side effects. The diagnostic radiopharmaceuticals segment follows closely, with PET tracers and SPECT tracers leading the charge due to their enhanced imaging capabilities. The growing prevalence of cardiovascular and neurological disorders further fuels demand for these diagnostic agents. Emerging technologies in radiopharmaceutical production, such as automated synthesis modules and cyclotron advancements, are boosting efficiency and scalability. Additionally, partnerships between pharmaceutical companies and research institutions are fostering innovation and accelerating the development of novel radiopharmaceuticals. Stringent regulatory frameworks and quality standards ensure the safety and efficacy of these products, enhancing market credibility and trust among healthcare providers.

Market Segmentation
TypeDiagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals, Research Radiopharmaceuticals
ProductTechnetium-99m, Iodine-131, Fluorodeoxyglucose (FDG), Gallium-68, Yttrium-90, Lutetium-177, Radium-223
ServicesContract Manufacturing, Quality Assurance, Regulatory Support, Logistics and Supply Chain Management
TechnologyCyclotron, Nuclear Reactor, Generator, Linear Accelerator
ApplicationOncology, Cardiology, Neurology, Endocrinology
FormLiquid, Solid, Gas
End UserHospitals, Diagnostic Centers, Academic and Research Institutes, Pharmaceutical Companies
ProcessSynthesis, Purification, Labeling, Packaging
EquipmentPET Scanners, SPECT Scanners, Gamma Cameras
SolutionsImaging Solutions, Therapeutic Solutions, Radiopharmacy Solutions

Market Snapshot:

The Radiopharmaceutical Manufacturing Market is witnessing a dynamic landscape with robust market share distribution influenced by strategic pricing and innovative product launches. Key industry players are focusing on expanding their portfolios, introducing new radiopharmaceuticals to meet growing demand for precision medicine. This strategic expansion is driven by advancements in nuclear medicine and the increasing prevalence of chronic diseases. The market is characterized by a competitive pricing strategy that balances affordability with cutting-edge technology, ensuring accessibility to a broader demographic. Competition within the Radiopharmaceutical Manufacturing Market is intense, with major firms vying for dominance through technological innovation and strategic partnerships. Regulatory influences play a pivotal role, with stringent guidelines shaping market practices and ensuring safety and efficacy. North America and Europe maintain leadership due to robust regulatory frameworks, while Asia-Pacific emerges as a lucrative growth region. The market's future is promising, with ongoing research and development fostering novel applications in diagnostic and therapeutic areas.

Geographical Overview:

The radiopharmaceutical manufacturing market is witnessing notable growth across various regions, each presenting unique opportunities. North America leads, driven by advanced healthcare infrastructure and increasing adoption of nuclear medicine. The presence of key industry players and a robust regulatory framework further bolster the market's expansion. Europe follows closely, with significant investments in research and development of novel radiopharmaceuticals. The region's strong focus on cancer treatment and neurological disorders enhances its market growth. In the Asia Pacific, rapid technological advancements and rising healthcare expenditure are propelling the market. Countries like China and India are emerging as lucrative growth pockets due to their large patient populations and increasing demand for diagnostic and therapeutic radiopharmaceuticals. Latin America and the Middle East & Africa are also witnessing growth, albeit at a slower pace. In Latin America, improving healthcare infrastructure and growing awareness about nuclear medicine are key drivers. Meanwhile, the Middle East & Africa are recognizing the potential of radiopharmaceuticals in addressing unmet medical needs.

Key Trends and Drivers:

The radiopharmaceutical manufacturing market is experiencing robust expansion, driven by advancements in molecular imaging and targeted therapies. A key trend is the increasing adoption of PET and SPECT imaging technologies, which offer enhanced diagnostic accuracy and personalized treatment options. The rising prevalence of cancer and cardiovascular diseases is propelling demand for these technologies, as they enable early detection and effective monitoring. Regulatory approvals and collaborations between pharmaceutical companies and research institutions are accelerating innovation in radiopharmaceuticals. The development of novel radioisotopes and radiolabeled compounds is expanding the therapeutic scope, creating lucrative opportunities for market players. Additionally, the integration of artificial intelligence in imaging systems is enhancing diagnostic capabilities, further boosting market growth. Growing investments in healthcare infrastructure, particularly in emerging economies, are facilitating the establishment of new manufacturing facilities. This trend is supported by government initiatives aimed at improving access to advanced medical technologies. The market is poised for sustained growth as these factors converge to meet the increasing demand for precise and effective diagnostic solutions.

Restraints and Challenges:

The Radiopharmaceutical Manufacturing Market encounters several significant restraints and challenges. Regulatory complexities present a formidable barrier, as stringent guidelines govern the production and distribution of radiopharmaceuticals. Compliance with these regulations demands substantial investment in time and resources, potentially stifling innovation and market entry. Another challenge is the limited availability of raw materials, particularly isotopes, which are critical for manufacturing. This scarcity can lead to supply chain disruptions, affecting production schedules and increasing costs. Furthermore, the high cost of production facilities and equipment poses a significant financial burden, especially for new entrants. The market also grapples with the need for highly specialized workforce. The recruitment and retention of skilled professionals are essential, yet challenging, due to the niche nature of the industry. Lastly, public perception and safety concerns about radioactive materials can hinder market growth, necessitating robust education and communication strategies to build trust.

Key Players:

Advanced Accelerator Applications, Blue Earth Diagnostics, ITM Isotopen Technologien M\unchen, Cyclopharm, NorthStar Medical Radioisotopes, Jubilant Radiopharma, Sofie Biosciences, Shine Medical Technologies, Eckert & Ziegler, Isotopia Molecular Imaging, Curium Pharma, Trace-Ability, Telix Pharmaceuticals, Alpha Tau Medical, Radiomedix

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by Form
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Equipment
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Diagnostic Radiopharmaceuticals
    • 4.1.2 Therapeutic Radiopharmaceuticals
    • 4.1.3 Research Radiopharmaceuticals
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Technetium-99m
    • 4.2.2 Iodine-131
    • 4.2.3 Fluorodeoxyglucose (FDG)
    • 4.2.4 Gallium-68
    • 4.2.5 Yttrium-90
    • 4.2.6 Lutetium-177
    • 4.2.7 Radium-223
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Contract Manufacturing
    • 4.3.2 Quality Assurance
    • 4.3.3 Regulatory Support
    • 4.3.4 Logistics and Supply Chain Management
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Cyclotron
    • 4.4.2 Nuclear Reactor
    • 4.4.3 Generator
    • 4.4.4 Linear Accelerator
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Cardiology
    • 4.5.3 Neurology
    • 4.5.4 Endocrinology
  • 4.6 Market Size & Forecast by Form (2020-2035)
    • 4.6.1 Liquid
    • 4.6.2 Solid
    • 4.6.3 Gas
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Hospitals
    • 4.7.2 Diagnostic Centers
    • 4.7.3 Academic and Research Institutes
    • 4.7.4 Pharmaceutical Companies
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Synthesis
    • 4.8.2 Purification
    • 4.8.3 Labeling
    • 4.8.4 Packaging
  • 4.9 Market Size & Forecast by Equipment (2020-2035)
    • 4.9.1 PET Scanners
    • 4.9.2 SPECT Scanners
    • 4.9.3 Gamma Cameras
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Imaging Solutions
    • 4.10.2 Therapeutic Solutions
    • 4.10.3 Radiopharmacy Solutions

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 Form
      • 5.2.1.7 End User
      • 5.2.1.8 Process
      • 5.2.1.9 Equipment
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 Form
      • 5.2.2.7 End User
      • 5.2.2.8 Process
      • 5.2.2.9 Equipment
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 Form
      • 5.2.3.7 End User
      • 5.2.3.8 Process
      • 5.2.3.9 Equipment
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 Form
      • 5.3.1.7 End User
      • 5.3.1.8 Process
      • 5.3.1.9 Equipment
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 Form
      • 5.3.2.7 End User
      • 5.3.2.8 Process
      • 5.3.2.9 Equipment
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 Form
      • 5.3.3.7 End User
      • 5.3.3.8 Process
      • 5.3.3.9 Equipment
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 Form
      • 5.4.1.7 End User
      • 5.4.1.8 Process
      • 5.4.1.9 Equipment
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 Form
      • 5.4.2.7 End User
      • 5.4.2.8 Process
      • 5.4.2.9 Equipment
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 Form
      • 5.4.3.7 End User
      • 5.4.3.8 Process
      • 5.4.3.9 Equipment
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 Form
      • 5.4.4.7 End User
      • 5.4.4.8 Process
      • 5.4.4.9 Equipment
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 Form
      • 5.4.5.7 End User
      • 5.4.5.8 Process
      • 5.4.5.9 Equipment
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 Form
      • 5.4.6.7 End User
      • 5.4.6.8 Process
      • 5.4.6.9 Equipment
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 Form
      • 5.4.7.7 End User
      • 5.4.7.8 Process
      • 5.4.7.9 Equipment
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 Form
      • 5.5.1.7 End User
      • 5.5.1.8 Process
      • 5.5.1.9 Equipment
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 Form
      • 5.5.2.7 End User
      • 5.5.2.8 Process
      • 5.5.2.9 Equipment
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 Form
      • 5.5.3.7 End User
      • 5.5.3.8 Process
      • 5.5.3.9 Equipment
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 Form
      • 5.5.4.7 End User
      • 5.5.4.8 Process
      • 5.5.4.9 Equipment
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 Form
      • 5.5.5.7 End User
      • 5.5.5.8 Process
      • 5.5.5.9 Equipment
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 Form
      • 5.5.6.7 End User
      • 5.5.6.8 Process
      • 5.5.6.9 Equipment
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 Form
      • 5.6.1.7 End User
      • 5.6.1.8 Process
      • 5.6.1.9 Equipment
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 Form
      • 5.6.2.7 End User
      • 5.6.2.8 Process
      • 5.6.2.9 Equipment
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 Form
      • 5.6.3.7 End User
      • 5.6.3.8 Process
      • 5.6.3.9 Equipment
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 Form
      • 5.6.4.7 End User
      • 5.6.4.8 Process
      • 5.6.4.9 Equipment
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 Form
      • 5.6.5.7 End User
      • 5.6.5.8 Process
      • 5.6.5.9 Equipment
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Advanced Accelerator Applications
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Blue Earth Diagnostics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 ITM Isotopen Technologien Munchen
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Cyclopharm
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 NorthStar Medical Radioisotopes
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Jubilant Radiopharma
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Sofie Biosciences
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Shine Medical Technologies
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Eckert & Ziegler
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Isotopia Molecular Imaging
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Curium Pharma
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Trace-Ability
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Telix Pharmaceuticals
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Alpha Tau Medical
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Radiomedix
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us